Author + information
- Received April 4, 2018
- Revision received April 26, 2018
- Accepted May 3, 2018
- Published online August 6, 2018.
- Teodora Donisan, MDa,
- Dinu Valentin Balanescu, MDa,
- Juan Carlos Lopez-Mattei, MDa,
- Peter Kim, MDa,
- Monika Jacquelina Leja, MDb,
- Jose Banchs, MDa,
- Konstantinos Marmagkiolis, MDc,
- Joerg Herrmann, MDd,
- Igor Gregoric, MDe,
- Jean-Bernard Durand, MDa and
- Cezar Angi Iliescu, MDa,∗ ()
- aDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas
- bDepartment of Internal Medicine and Cardiology, University of Michigan, Northville, Michigan
- cFlorida Hospital Pepin Heart Institute, Tampa, Florida
- dDivision of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
- eDepartment of Cardiothoracic and Vascular Surgery, Center for Advanced Heart Failure, The University of Texas Health Science Center at Houston/Memorial Hermann Hospital, Houston, Texas
- ↵∗Address for correspondence:
Dr. Cezar Angi Iliescu, Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, Texas 77030.
Primary cardiac tumors are rare, with myxoma being the most common benign histology, whereas malignancies are usually sarcomatous (1). They are found incidentally or on imaging prompted by flow obstruction or valvular dysfunction symptoms. The presence of cardiac tumors imposes a complete multimodality evaluation (Figures 1, 2, 3, and 4⇓⇓⇓⇓). Transthoracic echocardiography is an appropriate initial imaging modality due to its wide availability and lack of radiation, but it provides limited tissue characterization (2). Cardiac magnetic resonance is the reference modality for differentiation and characterization of cardiac masses (2). Computed tomography or positron emission tomography are useful complementary tests for patients unable to undergo cardiac magnetic resonance or for distinguishing between benign and malignant tumors (1). Even with the established imaging diagnosis of cardiac tumor, “the tissue is the issue.” Imaging-guided management should involve histopathologic diagnosis via biopsy, which is fundamental in this era of personalized cancer care. Data regarding cardiac tumor biopsies is limited.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received April 4, 2018.
- Revision received April 26, 2018.
- Accepted May 3, 2018.
- 2018 American College of Cardiology Foundation